Rhythm Pharmaceuticals price target lowered to $110 from $125 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target connected Rhythm Pharmaceuticals (RYTM) to $110 from $125 and keeps a Buy standing connected the shares, reflecting adjustments to the firm’s semipermanent income ramp expectations aft Rhythm precocious announced its Q4 results and announced further affirmative information from its planetary Phase 3 TRANSCEND proceedings of setmelanotide successful patients with acquired hypothalamic obesity.

Claim 70% Off TipRanks Premium

• Unlock hedge fund-level information and almighty investing tools for smarter, sharper decisions

• Stay up of the marketplace with the latest quality and investigation and maximize your portfolio's potential

Published archetypal connected TheFly – the eventual root for real-time, market-moving breaking fiscal news. Try Now>>

See today’s best-performing stocks connected TipRanks >>

Read More connected RYTM:

Disclaimer & DisclosureReport an Issue

• Rhythm Highlights Positive Phase 3 Data successful Hypothalamic Obesity

• Rhythm Pharmaceuticals terms people lowered to $140 from $141 astatine Canaccord

• Rhythm announces further information from Phase 3 proceedings of setmelanotide

• Rhythm Pharmaceuticals terms people raised to $143 from $140 astatine Guggenheim

• Rhythm Pharmaceuticals terms people lowered to $136 from $145 astatine Wells Fargo